Table 1.
Total number (N) and percentage (%) of gout patients in cohort A and cohort B receiving urate lowering therapy (ULT) grouped per ULT type, including the maximum and current mean serum urate (sUA) levels and sUA targets met within each ULT treatment group
| Type of ULT treatment | N (%a) | Mean (SD) sUA µmol/L maximum | Mean (SD) sUA µmol/L current | sUA <360 µmol/L, N (%) | sUA <300 µmol/L, N (%) |
|---|---|---|---|---|---|
| Cohort A | |||||
| Allopurinol monotherapy | 58 (58.6) | 558 (94) | 300 (86) | 45 (77.6) | 31 (53.4) |
| Febuxostat monotherapy | 16 (16.2) | 598 (99) | 277 (85) | 14 (87.5) | 11 (68.8) |
| Benzbromarone monotherapy | 4 (4.0) | 608 (131) | 330 (65) | 2 (50.0) | 1 (25.0) |
| Allopurinol/benzbromarone combination therapyb | 15 (15.2) | 612 (120) | 213 (82) | 14 (93.3) | 13 (86.7) |
| Febuxostat/benzbromarone combination therapyb | 6 (6.1) | 793 (163) | 255 (91) | 5 (83.3) | 4 (66.7) |
| Cohort B | |||||
| Allopurinol monotherapy | 66 (84.6) | 540 (70) | 296 (70) | 57 (86.4) | 39 (59.1) |
| Febuxostat monotherapy | 6 (7.7) | 592 (111) | 380 (90) | 4 (66.7) | 1 (16.7) |
| Benzbromarone monotherapy | 5 (6.4) | 554 (81) | 234 (58) | 5 (100.0) | 4 (80.0) |
| No ULT | 1 (1.3) | NA | NA | NA | NA |
Total sample size of cohort A = 99 patients and cohort B = 78 patients
ULT urate lowering therapy, NA not applicable, SD standard deviation, sUA serum urate
a Sum of percentages within each cohort is equal to 100
b Combination therapy was only given in cohort A